Physician profile
Mark Correa
NPI 1962864488
$3,623.39
in general payments reported to CMS, 2019-2025
23 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $239 · 2021: $311 · 2022: $563 · 2023: $524 · 2024: $1,025 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.68 | 2019-2024 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $531.19 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $520.45 | 2019-2025 | |
| Leo Pharma INC. | $373.91 | 2021-2025 | Adbry |
| Ucb, INC. | $299.63 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $231.12 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $215.36 | 2019-2024 | |
| Celgene Corporation | $157.55 | 2019 | |
| Janssen Biotech, INC. | $140.71 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $93.25 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $85.13 | 2023-2024 | Vtama |
| Incyte Corporation | $63.42 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $57.57 | 2024-2025 | |
| Galderma Laboratories, L.P. | $41.51 | 2021-2025 | Nemluvio |
| Pfizer INC. | $37.89 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $37.30 | 2019-2023 | Valchlor |
| Amgen INC. | $31.79 | 2024-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $30.11 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $22.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.70 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.11 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.04 | 2024 | Nuzyra |
| Mayne Pharma Commercial LLC | $11.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.